This study verifies and characterizes a novel FOXM1 inhibitor STL001 that effectively antagonizes FOXM1 activity and sensitizes a variety of human cancers to a broad spectrum of traditionally used chemotherapy agents and may be suitable for further clinical evaluation in targeting chemotherapy-resistance solid tumors. The gene discussed is FOXM1; the disease is cancer.